Table 2.
Demographics of the 383 participants included in the ALFA+ CSF cohort.
| ALFA+ cohort (n = 383) | A−T− (n = 248) | A+T− (n = 104) | A+T+ (n = 31) | P‐value |
|---|---|---|---|---|
| Females, n (%) | 153 (61.7) | 60 (50.7) | 21 (67.7) | 0.60 |
| Age, mean (SD) | 60.5 (4.5) | 61.8 (5.0) | 63.8 (4.4)* | ˂0.0001 |
| Education years, mean (SD) | 13.6 (3.5) | 13.8 (3.5) | 11.9 (3.7)* | 0.031 |
| APOE‐ɛ4 carriers, n (%) | 105 (42.3) | 85 (81.7)* | 18 (58.1) | ˂0.0001 |
| MMSE score, mean (SD) | 29.2 (0.9) | 29.2 (0.9) | 28.8 (1.1) | 0.13 |
| Aβ PET (CL), mean (SD) | −4.5 (6.6) | 12.8 (17.2)* | 31.9 (27.1)* | ˂0.0001 |
| CSF p‐tau181 (pg/ml), mean (SD) | 13.9 (4.2) | 15.5 (4.1)* | 33.4 (11.7)* | ˂0.0001 |
| CSF p‐tau217 (pg/ml), mean (SD) | 3.9 (2.1) | 7.1 (4.2)* | 21.1 (12.0)* | ˂0.0001 |
| CSF p‐tau231 (pg/ml), mean (SD) | 5.9 (1.9) | 9.3 (4.1)* | 23.2 (10.3)* | ˂0.0001 |
| CSF p‐tau235 (pg/ml), mean (SD) | 12.5 (3.7) | 14.6 (4.4)* | 28.2 (7.6)* | ˂0.0001 |
| CSF t‐tau (pg/ml), mean (SD) | 175 (48.0) | 190 (44.8)* | 355 (84.7)* | ˂0.0001 |
| CSF Aβ1–42/40 (pg/ml), mean (SD) | 0.09 (0.01) | 0.05 (0.01)* | 0.04 (0.01)* | ˂0.0001 |
A, amyloid pathology negative (−) / positive (+); T, tau pathology negative (−) / positive (+); MMSE, Mini Mental State Examination; PET, positron emission tomography; CL, Centiloids; CSF, cerebrospinal fluid; Aβ, amyloid‐beta; SD, standard deviation.
Data are presented as mean (SD). Differences between groups were tested using one‐way ANOVA adjusted by age and sex, followed by Bonferroni‐corrected post‐hoc comparison (continues variables) or Fisher exact test (categorical values). Significant differences compared with A−T− (*).